A new study has shown that the drug terzepatide, also known as Mongaro, may help treat obstructive sleep apnea in obese people. Ab
Obstructive sleep apnea is the most common sleep-disordered breathing condition. It occurs when the airway repeatedly becomes blocked during sleep, causing breathing to stop and resume, and may lead to snoring, gasping, and frequent awakenings.
Researchers from the University of Pittsburgh Medical Center reviewed the results of two clinical trials involving 469 patients with moderate to severe obstructive sleep apnea.
Participants who received terzepate lost about one-fifth of their body weight, and their number of pauses in breathing decreased by more than 20 times per hour. The results showed that 42 to 50% of them were free of obstructive sleep apnea, compared to about three times less among those who received a placebo.
Researchers believe that weight loss is the primary factor behind this improvement, as fat accumulation around the neck can narrow the airway and make breathing more difficult during sleep.
However, the results do not suggest that terzepate can replace continuous positive airway pressure (CPAP), especially in patients with severe cases. CPAP remains a primary treatment for the condition and has reduced the number of apnea episodes by more than 30 times per hour in its users.
It also remains unclear whether the benefits of terzepate persist after discontinuation, given the possibility of weight regain. Previous studies have shown that regaining some weight after stopping weight-loss medications is common, which may lead to a recurrence of sleep apnea.
The study results were published in the JAMA Otolaryngology–Head & Neck Surgery journal.
what is your opinion on this news ?do let us know in the comments on tha comment box
if you liked this news article please share on friends & family & don't forget to follow on website & social media
